Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  221.25
+7.48 (3.50%)
AAPL  258.90
+5.40 (2.13%)
AMD  231.82
+10.29 (4.64%)
BAC  51.88
+1.60 (3.18%)
GOOG  314.74
+10.81 (3.56%)
META  612.42
+37.37 (6.50%)
MSFT  374.33
+2.04 (0.55%)
NVDA  182.08
+3.98 (2.23%)
ORCL  143.66
+0.49 (0.34%)
TSLA  343.25
-3.40 (-0.98%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.